Clinical Indications for Capecitabine
Capecitabine is FDA-approved for metastatic colorectal cancer as first-line monotherapy when fluoropyrimidine therapy is preferred, and for metastatic breast cancer either as monotherapy after anthracycline/taxane resistance or in combination with docetaxel after anthracycline failure. 1
FDA-Approved Indications
Colorectal Cancer
- First-line metastatic colorectal cancer when single-agent fluoropyrimidine therapy is preferred 1
- Adjuvant treatment of Dukes' C (stage III) colon cancer after complete resection 1
Breast Cancer
- Metastatic breast cancer resistant to both anthracycline and paclitaxel or when further anthracycline therapy is contraindicated (as monotherapy) 1
- Metastatic breast cancer after failure of prior anthracycline-based chemotherapy (in combination with docetaxel) 1
Guideline-Supported Indications Beyond FDA Label
Advanced/Metastatic Colorectal Cancer
Capecitabine is recommended in NCCN guidelines as part of combination regimens (CAPEOX) for advanced or metastatic colorectal cancer 2. The standard European dose is 1000 mg/m² twice daily for 14 days every 21 days, though North American patients may require lower doses due to increased toxicity 2.
Critical caveat: Single-agent capecitabine after progression on a fluoropyrimidine-containing regimen is ineffective and not recommended 2. Patients with diminished creatinine clearance require dose modification 2.
Pancreatic Adenocarcinoma
For patients with poor performance status and locally advanced or metastatic pancreatic cancer, capecitabine is a category 2B option 3. It serves as an alternative for patients unable to tolerate combination chemotherapy regimens.
Gastric and Gastroesophageal Cancer
Capecitabine-based regimens (particularly with platinum agents) are widely used for advanced gastric cancer 4. The REAL-2 trial demonstrated that capecitabine is as effective as infusional 5-FU in gastroesophageal cancers, with comparable toxicity profiles 4.
Triple-Negative Breast Cancer (TNBC)
For patients with TNBC and residual disease after preoperative chemotherapy, adjuvant capecitabine improves disease-free survival (HR 0.70) and overall survival (HR 0.59, particularly strong in TNBC with HR 0.52) 5. This is based on the CREATE-X trial and represents a critical indication for improving outcomes in high-risk TNBC patients.
Dosing Considerations
Standard Dosing
- FDA-approved dose: 1250 mg/m² orally twice daily for 14 days, followed by 7-day rest (21-day cycles) 1
- European standard: 1000 mg/m² twice daily for 14 days 2
Dose Modifications Required
- Moderate renal impairment (CrCl 30-50 mL/min): 75% dose reduction 1
- Severe renal impairment (CrCl <30 mL/min): Contraindicated 1
- Elderly patients: 20% increase in age results in 15% increase in FBAL exposure; monitor closely 1
- Hepatic dysfunction: Use with caution in mild-to-moderate hepatic impairment; capecitabine AUC and Cmax increase by 60% 1
Key Safety Considerations
Must be taken with food (within 30 minutes after a meal) as food reduces Cmax by 60% and AUC by 35%, which is factored into dosing recommendations 1.
Common dose-limiting toxicities include hand-foot syndrome, diarrhea, and hyperbilirubinemia 1. Compared to bolus 5-FU/LV, capecitabine causes more hand-foot syndrome but less stomatitis, alopecia, and neutropenia 1.
Critical drug interaction: Capecitabine increases warfarin AUC by 57% and INR by 2.8-fold, requiring close INR monitoring 1.
Dihydropyrimidine dehydrogenase (DPD) deficiency increases risk of severe, life-threatening toxicity; consider testing in patients with severe early toxicity 6.